Mechanical valves used for aortic valve replacement (AVR) continue to be associated with
bleeding risks because of anticoagulation therapy, while bioprosthetic valves are at risk of …

This chapter about antithrombotic therapy in native and prosthetic valvular heart disease is
part of the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy …

After publication, dissemination of the message is of paramount importance. Publication of
executive summaries and the production of pocket-sized and PDA-downloadable versions …

Choosing the right valve for the right patient is a difficult but essential process to optimize the
outcome for patients undergoing valve replacement. The first step in this decisionmaking …

This chapter about antithrombotic therapy for valvular heart disease is part of the American
College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) …

Over 4 million people worldwide have received a prosthetic heart valve, and an estimated
300 000 valves are being implanted every year. Prosthetic heart valves improve quality of …

This document presents a professional view of evidence-based recommendations around
the issues of antiplatelet and anticoagulation management in cardiac surgery. It was …

Approximately 50 000 valve replacement operations take place in Europe annually and
almost as many valve repair procedures. Previous European guidelines on management of …

Context The need for anticoagulation after surgical aortic valve replacement (AVR) with
biological prostheses is not well examined. Objective To perform a nationwide study of the …

Objectives: This study assesses if there exists a high-risk period for cerebrovascular events
(CeV) after transcatheter aortic valve implantation (TAVI). Background: Even though acute …